the social development partnerships program – disability (sdpp-d) component supports projects intended to improve the participation and increase the social inclusion of persons with disabilities in all aspects of canadian society.

we are now accepting applications for projects aimed at developing the next generation of youth disability leaders while also facilitating succession planning and sustainability in the disability sector. up to $50,000 per year (to a maximum of $150, 000 over 3 years) in contribution, funding is available from sdpp-d for organizations to form a partnership between a national disability organization and an organization- within or outside of the disability sector – that is actively engaging youth. the projects will provide meaningful leadership experiences to youth with disabilities or youth with lived experience. projects can range from a minimum of 12 months up to a maximum of 36 months in duration.

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha) research and development directorate j9 manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

the fy19 aimm program announcement and general application instructions for the following award mechanism are posted on grants.gov. 

applications submitted to the fy19 aimm initiative must address at least one of the following focus areas:

• ·          algorithms/tools for decision support in a deployed or operational environment to: diagnose military-relevant disease, illness, or injury; prescribe mitigation and treatment strategies; and/or determine risk of warfighter return to duty.    
• ·          artificial intelligence (ai)/deep learning for integrating heterogeneous data streams and analyzing data from wearables to support making informed healthcare decisions.  wearable sensor systems may pertain to, but are not limited to, the following or combinations of the following:  infectious disease diagnosis; physiologic status monitoring; informing real-time casualty location and triage; and/or environmental monitoring.     
• ·          ai/deep learning for analyzing and interrogating large medical data sets to: identify patterns/predictors of disease, illness, or injury; and/or identify treatment outcomes.

https://cdmrp.army.mil/funding/dmrdp

aimm research award – preproposal due july 26, 2019

independent investigators at all academic levels (or equivalent)

• supports highly creative and conceptually innovative high-risk research with the potential to accelerate critical discoveries or major advancements that will significantly impact military health and medicine; not intended to support incremental advances on previous or ongoing work.
• supports applied research efforts that initiate or enhance potential game-changers that may not be supported by other funding mechanisms or core programs.
• applications must address at least one of the fy19 focus areas, which include algorithms/tools for decision support in a deployed or operational environment, and ai/deep learning for integrating heterogeneous data streams and analyzing data from wearables to support making informed healthcare decisions, as well as for analyzing and interrogating large medical data sets
• cross-cutting, broadly applicable projects with the potential to benefit multiple dod medical research program areas are highly encouraged.
• presentation of preliminary data is not required, though not prohibited.

• ·         maximum funding of $350,000 for direct costs (plus indirect costs)
• ·         maximum period of performance is 18 months

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcement and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all usamrmc funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  submission deadlines are not available until the program announcement is released.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507
help@ebrap.org

wounded warriors doctoral scholarship in military and veteran health research.

awarded to a doctoral level student conducting research on issues relevant to military members, veterans and families.

value: $18,000/year for 2 years

deadline: september 4, 2019

$5,000 awarded to a postgraduate student to enhance their specialization in epidemiological and mental health problems in military personnel, veterans and /or their families.

this award honours the legacy of dr. mark zamorski, a specialist in epidemiological and health services research on mental health problems in military personnel and a steadfast cimvhr supporter.  dr. zamorski led the research and analysis section of the directorate of mental health for the canadian forces health services group from 2002 until his passing in 2018.

eligibility criteria:

• be registered as a full-time student in either the final year of a master’s program or in the final 2 years of a phd program at a canadian university;
• be conducting research that has significant potential to improve the mental health of veteran or military populations, or their families;
• exhibit significant potential for a high-impact research career in this area;
• demonstrate a high level of quality in proposed research methodology, and excellent analytical and writing skills;
• preference will be given to 世界杯2022赛程表淘汰赛 studying at one of cimvhr’s 44 partner universities.

the fy19 defense appropriation provides $3.2 million (m) to the department of defense duchenne muscular dystrophy research program (dmdrp) to support innovative, high-impact duchenne muscular dystrophy research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 dmdrp program announcement and general application instructions for the following award mechanism is posted on the grants.gov.

important:  all applications for the fy19 dmdrp idea development award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of dmd. eligible therapeutic strategies include: gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies.

studies proposed under this award may include:

• delivery to skeletal muscle and heart (ligand assisted, nanoparticles, identification of biological barriers to delivery, alternative vectors)
• immunosuppression, and other strategies to deal with neutralizing antibodies
• re-dosing
• targeting muscle stem cells
• cell based therapies, including but not limited to: selection of novel cell types, expansion, root of delivery, differentiation, and integration

studies proposed under this award should not include:

• therapies addressing secondary pathology of dmd (fibrosis, inflammation, muscle atrophy, oxidative stress, mitochondrial defects, abnormal peripheral circulation)
• small molecules
• efficacy testing absence of mechanistic understanding,
• evaluation of standard vectors or delivery technologies

https://cdmrp.army.mil/funding/dmdrp

idea development award

principal independent investigator (pi): independent investigators at all academic levels (or equivalent) are eligible to be names as a pi.

• supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accerale progress in improving outcomes for individuals with dmdm.
• applications must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology or dmd.
• preliminary data are required.
• clinical trials are not allowed.
• maximum funding of $350,000 in direct costs (plus indirect costs)
• period of performance not to exceed 2 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the dmdrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

the fy19 defense appropriation provides $20 million (m) to the department of defense vision research program (vrp) to support impactful military-relevant vision research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 vrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

applications submitted to the fy19 vrp must address at least one of the following focus areas:

• eye injury or visual dysfunction as related to a military-relevant traumatic event.  examples of military-relevant trauma may include, but are not limited to:

○        blast, blunt, thermal, or chemical trauma

○        trauma caused by directed energy weapons such as laser, microwaves, and particle beams

• diagnosis and treatment of eye injuries in austere environments and prolonged field care settings

https://cdmrp.army.mil/funding/vrp

focused translational team science award (fttsa) – preproposal due august 6, 2019

• the overall principal investigator (pi) must be an independent investigator at or above the level of associate professor (or equivalent) with demonstrated success in leading large collaborative research project(s).
• leaders of individual projects may be independent investigators at all academic levels (or equivalent).
• the overall lead pi is required to devote a minimum of 20% effort to this award.

preproposal is required; application submission is by invitation only.

• supports a highly collaborative and translational team initiative that will fundamentally advance the understanding and treatment of eye injury and/or visual dysfunction that result from a military-relevant trauma.

• must address one or more of the fy19 vrp focus areas.

• applications shall include at least three but no more than five distinct research projects that together form a concerted and synergistic effort to address an overarching challenge.

• preliminary data required for each individual project.

• one of the projects may include a pilot clinical trial where limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials.

• must have a detailed implementation plan for participating research groups to coordinate efforts, facilitate collaboration, and create synergy.

○        maximum funding of $5,000,000 for direct costs (plus indirect costs)

○        the maximum period of performance is 4 years.

investigator-initiated research award (iira) – preproposal due august 6, 2019

independent investigators at all academic levels (or equivalent).

preproposal is required; application submission is by invitation only.

• supports studies that will yield highly impactful discoveries or major advancements in research and/or patient care of eye injury and/or visual dysfunction as related to military-relevant trauma.
• must address one or more of the fy19 vrp focus areas.
• funding level 1 supports exploratory, high-risk/high-reward research in the earliest stages of development. no preliminary data is required.
• funding level 2 supports the advancement of more mature research toward clinical translation.  preliminary data required. 
• it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  the funding level should be selected based on the stage and maturity of the research, rather than the amount of the budget.
• clinical trials are not allowed

funding level 1:

• maximum funding of $260,000 for direct costs (plus indirect costs)
• the maximum period of performance is 2 years.

funding level 2:

• maximum funding of $500,000 for direct costs (plus indirect costs)
• the maximum period of performance is 3 years.

translational research award (tra) – preproposal due august 6, 2019

independent investigators at all academic levels (or equivalent).

preproposal is required; application submission is by invitation only.

• supports translational research that moves promising laboratory research into clinical applications.
• it is expected that an investigational new drug (ind)/investigational device exemption (ide) application will be submitted during or by the end of the period of performance.
• must address one or more of the fy19 vrp focus areas.
• preliminary data required.
  • may include a pilot clinical trial component where limited clinical limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials.
  • maximum funding of $750,000 for direct costs (plus indirect costs)
  • the maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.  

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org/.  for more information about the vrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

cihr-icr is committed to supporting and promoting the success of early career researchers (ecrs). in response, this funding opportunity is part of a suite of activities icr is undertaking in support of ecrs and intends to contribute to the long-term success of ecrs by giving them leadership opportunities and contributing to their development as future leaders. this funding opportunity will also focus on the mentorship of ecrs and building capacity with a specific emphasis on cancer research across the cancer control continuum. recognizing ongoing efforts to harmonize across the tri-agencies, for the purpose of this funding opportunity, ecrs are referred to as new investigators and defined in line with the tfri definition, i.e., researchers who are within seven calendar years from the start of their first faculty-level appointment.

there has been a move towards more collaborative science with large teams. new investigators may be challenged with getting involved and having a meaningful role in team science. the tfri, a national funding agency, runs an annual competition to support new investigators to be mentored as part of their funded teams’ activities. the current competition will expand this program to teams funded by tfri and icr. the goal of the program is to support outstanding new investigators as they develop their careers as independent research scientists or clinician scientists, to undertake high-quality cancer research, while in close collaboration and mentorship with established tfri or cihr-icr-funded research teams. support will target high-quality research in all four funding pillars, providing information that may form the basis of innovative cancer prevention, diagnosis and/or treatment across the cancer control continuum.

the cihr-icrh/caaif/astrazeneca/allergen emerging researcher award is expected to:

• increase canadian research capacity in the area of asthma;
• support the research careers of promising researchers;
• produce high-quality research in asthma; and
• contribute to knowledge translation activities.

this funding opportunity is expected to:

• catalyze the transfer of health research knowledge related to sex, gender and diversity into health policy development and practice.
• foster capacity development and the creation of best practices to support the sustainable application of evidence-based sex, gender and diversity analysis to health policies and programs.
• support the scientifically rigorous evaluation of outcomes related to the integration of sex, gender and diversity in health policies and programs.

this clinician-scientist award program is a collaboration between the canadian lung association (cla), cihr’s institute of circulatory and respiratory health (cihr-icrh) and astrazeneca (az) canada. the goal of the award is to support emerging clinician scientists (e.g., doctor of medicine, doctor of medicine–doctor of philosophy, doctor of dental sciences, phd–respiratory therapist, phd–registered nurse, phd-physiotherapist, phd–occupational therapist or equivalent) within the first five (5) years of their first faculty appointment in the establishment of their careers.